Fingolimod: Lessons Learned and New Opportunities for Treating Multiple Sclerosis and Other Disorders

Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1

Matloubian, M., Lo, C. G., Cinamon, G., Lesneski, M. J., Xu, Y., Brinkmann, V., Allende, M. L., Proia, R. L., & Cyster, J. G. (2004) · Nature · doi:10.1038/nature02284 · Cited by 2,581 · see citing works

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.

Kappos, L., Radue, E., O'Connor, P., Polman, C., Hohlfeld, R., Calabresi, P., Selmaj, K., Agoropoulou, C., Leyk, M., Zhang-Auberson, L., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909494 · Cited by 2,569 · see citing works

Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis

Cohen, J. A., Barkhof, F., Comı, G., Hartung, H., Khatri, B. O., Montalbán, X., Pelletier, J., Capra, R., Gallo, P., Izquierdo, G., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907839 · Cited by 2,199 · see citing works

Alteration of Lymphocyte Trafficking by Sphingosine-1-Phosphate Receptor Agonists

MANDALA, S. M., Hajdu, R., Bergstrom, J. D., Quackenbush, E. J., Xie, J., Milligan, J. A., Thornton, R. A., Shei, G.-J., Card, D., Keohane, C.-A., et al. (2002) · Science · doi:10.1126/science.1070238 · Cited by 1,691 · see citing works

The Immune Modulator FTY720 Targets Sphingosine 1-Phosphate Receptors

Brinkmann, V., Davis, M. D., Heise, C. E., Albert, R., Cottens, S., Hof, R., Bruns, C., Prieschl, E. E., Baumruker, T., HIESTAND, P. C., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.c200176200 · Cited by 1,506 · see citing works

Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis

Brinkmann, V., Billich, A., Baumruker, T., Heining, P., Schmouder, R., Francis, G., Aradhye, S., & Burtin, P. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3248 · Cited by 1,273 · see citing works

Edg-1, the G protein–coupled receptor for sphingosine-1-phosphate, is essential for vascular maturation

Liu, Y., Wada, R., Yamashita, T., Mi, Y., Deng, C., Hobson, J. P., Rosenfeldt, H. M., Nava, V. E., Chae, S.-S., Lee, M.-J., et al. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10905 · Cited by 1,144 · see citing works

Oral Fingolimod (FTY720) for Relapsing Multiple Sclerosis

Kappos, L., Antel, J. P., Comi, G., Montalbán, X., O'Connor, P. W., Polman, C. H., Haas, T., Korn, A., Karlsson, G., & Radue, E. W. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052643 · Cited by 1,047 · see citing works

Multiple Sclerosis: Current Knowledge and Future Outlook

Kamm, C. P., Uitdehaag, B. M. J., & Polman, C. H. (2014) · European Neurology · doi:10.1159/000360528 · Cited by 1,011 · see citing works

Sphingosine-1-Phosphate as a Ligand for the G Protein-Coupled Receptor EDG-1

Lee, M.-J., Brocklyn, J. R. V., Thangada, S., Liu, C. H., Hand, A. R., Menzeleev, R., Spiegel, S., & Hla, T. (1998) · Science · doi:10.1126/science.279.5356.1552 · Cited by 1,007 · see citing works

Multiple Sclerosis: Mechanisms and Immunotherapy

Baecher-Allan, C., Kaskow, B. J., & Weiner, H. L. (2018) · Neuron · doi:10.1016/j.neuron.2018.01.021 · Cited by 938 · see citing works

Sphingosine-1-phosphate as second messenger in cell proliferation induced by PDGF and FCS mitogens

Olivera, A., & Spiegel, S. (1993) · Nature · doi:10.1038/365557a0 · Cited by 895 · see citing works

Promotion of Lymphocyte Egress into Blood and Lymph by Distinct Sources of Sphingosine-1-Phosphate

Pappu, R., Schwab, S. R., Cornelissen, I., Pereira, J. P., Regard, J. B., Xu, Y., Camerer, E., Zheng, Y., Huang, Y., Cyster, J. G., et al. (2007) · Science · doi:10.1126/science.1139221 · Cited by 874 · see citing works

LPA Receptors: Subtypes and Biological Actions

Choi, J. W., Herr, D. R., Noguchi, K., Yung, Y. C., Lee, C., Mutoh, T., Lin, M., Teo, S. T., Park, K. E., Austin, A. M., et al. (2010) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.010909.105753 · Cited by 840 · see citing works

Lysophosphatidate-induced cell proliferation: Identification and dissection of signaling pathways mediated by G proteins

van Corven, E. J., Groenink, A., Jalink, K., Eichholtz, T. J., & Moolenaar, W. H. (1989) · Cell · doi:10.1016/0092-8674(89)90868-4 · Cited by 836 · see citing works

Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial

Calabresi, P. A., Radue, E. W., Goodin, D. S., Jeffery, D., Rammohan, K. W., Reder, A. T., Vollmer, T. L., Agius, M. A., Kappos, L., Stites, T. E., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70049-3 · Cited by 825 · see citing works

Sphingosine-1-Phosphate and Lymphocyte Egress from Lymphoid Organs

Cyster, J. G., & Schwab, S. R. (2012) · Annual Review of Immunology · doi:10.1146/annurev-immunol-020711-075011 · Cited by 820 · see citing works

Mechanism of Action of Oral Fingolimod (FTY720) in Multiple Sclerosis

Chun, J., & Hartung, H.-P. (2010) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e3181cbf825 · Cited by 796 · see citing works

Lysophospholipid Receptors: Signaling and Biology

Ishii, I., Fukushima, N., Ye, X., & Chun, J. J. M. (2004) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.73.011303.073731 · Cited by 771 · see citing works

Ventricular zone gene-1 (vzg-1) encodes a lysophosphatidic acid receptor expressed in neurogenic regions of the developing cerebral cortex.

Hecht, J. H., Weiner, J. A., Post, S. R., & Chun, J. J. M. (1996) · The Journal of Cell Biology · doi:10.1083/jcb.135.4.1071 · Cited by 718 · see citing works

LPA receptor signaling: pharmacology, physiology, and pathophysiology

Yung, Y. C., Lummis, N. C., & Chun, J. J. M. (2014) · Journal of Lipid Research · doi:10.1194/jlr.r046458 · Cited by 717 · see citing works

GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current

Lauckner, J. E., Jensen, J. B., Chen, H.-Y., Lu, H., Hille, B., & Mackie, K. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711278105 · Cited by 710 · see citing works

Crystal Structure of a Lipid G Protein–Coupled Receptor

Hanson, M. A., Roth, C., Jo, E., Griffith, M. T., Scott, F. L., Reinhart, G. J., Desale, H., Clemons, B., Cahalan, S. M., Schuerer, S. C., et al. (2012) · Science · doi:10.1126/science.1215904 · Cited by 667 · see citing works

FTY720, a Novel Immunosuppressant, Induces Sequestration of Circulating Mature Lymphocytes by Acceleration of Lymphocyte Homing in Rats. I. FTY720 Selectively Decreases the Number of Circulating Mature Lymphocytes by Acceleration of Lymphocyte Homing

Chiba, K., Yanagawa, Y., Masubuchi, Y., Kataoka, H., Kawaguchi, T., Ohtsuki, M., & Hoshino, Y. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.10.5037 · Cited by 597 · see citing works

FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P 1 ) modulation

Choi, J. W., Gardell, S. E., Herr, D. R., Rivera, R. R., Lee, C., Noguchi, K., Teo, S. T., Yung, Y. C., Lu, M., Kennedy, G., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1014154108 · Cited by 582 · see citing works

LPA3-mediated lysophosphatidic acid signalling in embryo implantation and spacing

Ye, X., Hama, K., Contos, J. J. A., Anliker, B., Inoue, A., Skinner, M. K., Suzuki, H., Amano, T., Kennedy, G., Arai, H., et al. (2005) · Nature · doi:10.1038/nature03505 · Cited by 563 · see citing works

Identification of an intracellular receptor for lysophosphatidic acid (LPA): LPA is a transcellular PPARγ agonist

McIntyre, T. M., Pontsler, A. V., Silva, A. R., Hilaire, A. S., Xu, Y., Hinshaw, J. C., Zimmerman, G. A., Hama, K., Aoki, J., Arai, H., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0135855100 · Cited by 550 · see citing works

Fungal metabolites. Part 11. A potent immunosuppressive activity found in Isaria sinclairii metabolite.

Fujita, T., Inoue, K., Yamamoto, S., Ikumoto, T., Sasaki, S., TOYAMA, R., Chiba, K., Hoshino, Y., & Okumoto, T. (1994) · The Journal of Antibiotics · doi:10.7164/antibiotics.47.208 · Cited by 541 · see citing works

Serine Palmitoyltransferase Is the Primary Target of a Sphingosine-like Immunosuppressant, ISP-1/Myriocin

Miyake, Y., Kozutsumi, Y., Nakamura, S., Fujita, T., & Kawasaki, T. (1995) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1995.1827 · Cited by 536 · see citing works

Characterization of a Novel Subtype of Human G Protein-coupled Receptor for Lysophosphatidic Acid

An, S. M., Bleu, T., Hallmark, O. G., & Goetzl, E. J. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.14.7906 · Cited by 528 · see citing works

An update on the biology of sphingosine 1-phosphate receptors

Blaho, V. A., & Hla, T. (2014) · Journal of Lipid Research · doi:10.1194/jlr.r046300 · Cited by 516 · see citing works

Molecular Cloning and Characterization of a Novel Human G-protein-coupled Receptor, EDG7, for Lysophosphatidic Acid

Bandoh, K., Aoki, J., Hosono, H., Kobayashi, S. S., Kobayashi, T., Murakami‐Murofushi, K., Tsujimoto, M., Arai, H., & Inoue, K. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.39.27776 · Cited by 511 · see citing works

Lysophosphatidic acid: G-protein signalling and cellular responses

Moolenaar, W. H., Kranenburg, O., Postma, F. R., & Zondag, G. C. M. (1997) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(97)80059-2 · Cited by 486 · see citing works

An abundant transcript induced in differentiating human endothelial cells encodes a polypeptide with structural similarities to G-protein-coupled receptors.

Hla, T., & Maciag, T. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)38849-0 · Cited by 484 · see citing works

Requirement for the lp A1 lysophosphatidic acid receptor gene in normal suckling behavior

Contos, J. J. A., Fukushima, N., Weiner, J. A., Kaushal, D., & Chun, J. J. M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.24.13384 · Cited by 478 · see citing works

FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system

Brinkmann, V. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00451.x · Cited by 438 · see citing works

The Sphingosine-1-phosphate Receptors S1P1, S1P2, and S1P3 Function Coordinately during Embryonic Angiogenesis

Kono, M., Mi, Y., Liu, Y., Sasaki, T., Allende, M. L., Wu, Y., Yamashita, T., & Proia, R. L. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m403937200 · Cited by 415 · see citing works

Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis

Cohen, J. A., & Chun, J. J. M. (2011) · Annals of Neurology · doi:10.1002/ana.22426 · Cited by 394 · see citing works

TGFα shedding assay: an accurate and versatile method for detecting GPCR activation

Inoue, A., Ishiguro, J., Kitamura, H., Arima, N., Okutani, M., Shuto, A., Higashiyama, S., Ohwada, T., Arai, H., Makide, K., et al. (2012) · Nature Methods · doi:10.1038/nmeth.2172 · Cited by 363 · see citing works

FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis

Mehling, M., Brinkmann, V., Antel, J. P., Bar‐Or, A., Goebels, N., Védrine, C., Kristofic, C., Kühle, J., Lindberg, R. L. P., & Kappos, L. (2008) · Neurology · doi:10.1212/01.wnl.0000327609.57688.ea · Cited by 340 · see citing works

T-bet–dependent S1P5 expression in NK cells promotes egress from lymph nodes and bone marrow

Jenne, C. N., Enders, A., Rivera, R. R., Watson, S. R., Bankovich, A. J., Pereira, J. P., Xu, Y., Roots, C. M., Beilke, J. N., Banerjee, A., et al. (2009) · The Journal of Experimental Medicine · doi:10.1084/jem.20090525 · Cited by 334 · see citing works

International Union of Basic and Clinical Pharmacology. LXXVIII. Lysophospholipid Receptor Nomenclature

Chun, J. J. M., Hla, T., Lynch, K. R., Spiegel, S., & Moolenaar, W. H. (2010) · Pharmacological Reviews · doi:10.1124/pr.110.003111 · Cited by 330 · see citing works

Lysophospholipid receptor nomenclature review: IUPHAR Review 8

Kihara, Y., Maceyka, M. W., Spiegel, S., & Chun, J. J. M. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12678 · Cited by 325 · see citing works

Lysophospholipid Receptors

Fukushima, N., Ishii, I., Contos, J. J. A., Weiner, J. A., & Chun, J. J. M. (2001) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.41.1.507 · Cited by 322 · see citing works

Brain Penetration of the Oral Immunomodulatory Drug FTY720 and Its Phosphorylation in the Central Nervous System during Experimental Autoimmune Encephalomyelitis: Consequences for Mode of Action in Multiple Sclerosis

Foster, C. A., Howard, L. M., Schweitzer, A., Persohn, E., HIESTAND, P. C., Balatoni, B., Reuschel, R., Beerli, C., Schwartz, M., & Billich, A. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.127183 · Cited by 321 · see citing works

Characterization of lpa2 (Edg4) and lpa1/lpa2 (Edg2/Edg4) Lysophosphatidic Acid Receptor Knockout Mice: Signaling Deficits without Obvious Phenotypic Abnormality Attributable to lpa2

Contos, J. J. A., Ishii, I., Fukushima, N., Kingsbury, M. A., Ye, X., Kawamura, S., Brown, J. H., & Chun, J. J. M. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.19.6921-6929.2002 · Cited by 316 · see citing works

Fingolimod: Direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy

Groves, A., Kihara, Y., & Chun, J. J. M. (2013) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2013.02.011 · Cited by 314 · see citing works

Design, synthesis, and structure-activity relationships of 2-substituted-2-amino-1,3-propanediols: Discovery of a novel immunosuppressant, FTY720

Adachi, K., Kohara, T., Nakao, N., Arita, M., Chiba, K., Mishina, T., Sasaki, S., & Fujita, T. (1995) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/0960-894x(95)00127-f · Cited by 306 · see citing works

Impact of an immune modulator fingolimod on acute ischemic stroke

Fu, Y., Zhang, N., Ren, L., Yan, Y., Sun, N., Li, Y.-J., Han, W., Xue, R., Liu, Q., Hao, J., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1416166111 · Cited by 291 · see citing works

A NOVEL IMMUNOSUPPRESSANT, FTY720, WITH A UNIQUE MECHANISM OF ACTION, INDUCES LONG-TERM GRAFT ACCEPTANCE IN RAT AND DOG ALLOTRANSPLANTATION1

Suzuki, S., Enosawa, S., Kakefuda, T., Shinomiya, T., Amari, M., Naoe, S., Hoshino, Y., & Chiba, K. (1996) · Transplantation · doi:10.1097/00007890-199601270-00006 · Cited by 285 · see citing works

A single receptor encoded by vzg-1 / lp A1 / edg- 2 couples to G proteins and mediates multiple cellular responses to lysophosphatidic acid

Fukushima, N., Kimura, Y., & Chun, J. J. M. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6151 · Cited by 282 · see citing works

Amelioration of Experimental Autoimmune Encephalomyelitis in Lewis Rats by FTY720 Treatment

Fujino, M., Funeshima, N., Kitazawa, Y., Kimura, H., Amemiya, H., Suzuki, S., & Li, X. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.045658 · Cited by 279 · see citing works

Selective Loss of Sphingosine 1-Phosphate Signaling with No Obvious Phenotypic Abnormality in Mice Lacking Its G Protein-coupled Receptor, LPB3/EDG-3

Ishii, I., Friedman, B., Ye, X., Kawamura, S., McGiffert, C., Contos, J. J. A., Kingsbury, M. A., Zhang, G., Brown, J. H., & Chun, J. J. M. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m104441200 · Cited by 272 · see citing works

Fingolimod (FTY720) Enhances Remyelination Following Demyelination of Organotypic Cerebellar Slices

Miron, V. E., Ludwin, S. K., Darlington, P. J., Jarjour, A. A., Soliven, B. C., Kennedy, T. E., & Antel, J. P. (2010) · American Journal Of Pathology · doi:10.2353/ajpath.2010.091234 · Cited by 267 · see citing works

Lysophosphatidic Acid Signaling in the Nervous System

Yung, Y. C., Lummis, N. C., Mirendil, H., & Chun, J. J. M. (2015) · Neuron · doi:10.1016/j.neuron.2015.01.009 · Cited by 265 · see citing works

Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis

Zivadinov, R., Reder, A. T., Filippi, M., Minagar, A., Stüve, O., Lassmann, H., Racke, M. K., Dwyer, M. G., Frohman, E. M., & Khan, O. (2008) · Neurology · doi:10.1212/01.wnl.0000316810.01120.05 · Cited by 260 · see citing works

Schwann cell survival mediated by the signaling phospholipid lysophosphatidic acid

Weiner, J. A., & Chun, J. J. M. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.9.5233 · Cited by 257 · see citing works

Lysophospholipids and their receptors in the central nervous system

Choi, J. W., & Chun, J. J. M. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2012.07.015 · Cited by 255 · see citing works

Crystal structure of autotaxin and insight into GPCR activation by lipid mediators

Nishimasu, H., Okudaira, S., Hama, K., Mihara, E., Dohmae, N., Inoue, A., Ishitani, R., Takagi, J., Aoki, J., & Nureki, O. (2011) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1998 · Cited by 249 · see citing works

A treatise on the chemical constitution of the brain.

(1963) · JAMA · doi:10.1001/jama.1963.03700230140039 · Cited by 248 · see citing works

Identification of cDNAs encoding two G protein‐coupled receptors for lysosphingolipids1

An, S. M., Bleu, T., Huang, W., Hallmark, O. G., Coughlin, S. R., & Goetzl, E. J. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)01301-x · Cited by 244 · see citing works

Marked Perinatal Lethality and Cellular Signaling Deficits in Mice Null for the Two Sphingosine 1-Phosphate (S1P) Receptors, S1P2/LPB2/EDG-5 and S1P3/LPB3/EDG-3

Ishii, I., Ye, X., Friedman, B., Kawamura, S., Contos, J. J. A., Kingsbury, M. A., Yang, A. H., Zhang, G., Brown, J. H., & Chun, J. J. M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200137200 · Cited by 244 · see citing works

HDL-bound sphingosine-1-phosphate restrains lymphopoiesis and neuroinflammation

Blaho, V. A., Galvani, S., Engelbrecht, E., Liu, C., Swendeman, S. L., Kono, M., Proia, R. L., Steinman, L., Han, M. H., & Hla, T. (2015) · Nature · doi:10.1038/nature14462 · Cited by 229 · see citing works

Sphingosine 1-phosphate receptor agonists attenuate relapsing–remitting experimental autoimmune encephalitis in SJL mice

Webb, M., Tham, C., Lin, F., Lariosa-Willingham, K. D., Yu, N., Hale, J. J., MANDALA, S. M., Chun, J. J. M., & Rao, T. S. (2004) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2004.04.015 · Cited by 225 · see citing works

Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study

Khatri, B. O., Barkhof, F., Comi, G., Hartung, H.-P., Kappos, L., Montalbán, X., Pelletier, J., Stites, T. E., Wu, S., Holdbrook, F. K., et al. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70099-0 · Cited by 218 · see citing works

Lysophosphatidic acid as a lipid mediator with multiple biological actions

Aikawa, S., Hashimoto, T., Kano, K., & Aoki, J. (2014) · The Journal of Biochemistry · doi:10.1093/jb/mvu077 · Cited by 215 · see citing works

Fingolimod phosphate promotes the neuroprotective effects of microglia

Noda, H., Takeuchi, H., Mizuno, T., & Suzumura, A. (2013) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2012.12.005 · Cited by 212 · see citing works

Crystal Structure of Antagonist Bound Human Lysophosphatidic Acid Receptor 1

Chrencik, J., Roth, C., Terakado, M., Kurata, H., Omi, R., Kihara, Y., Warshaviak, D. T., Nakade, S., Asmar-Rovira, G. A., Mileni, M., et al. (2015) · Cell · doi:10.1016/j.cell.2015.06.002 · Cited by 205 · see citing works

Classifying PML risk with disease modifying therapies

Berger, J. R. (2017) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2017.01.006 · Cited by 203 · see citing works

MYRIOCIN, A NEW ANTIFUNGAL ANTIBIOTIC FROM MYRIOCOCCUM ALBOMYCES

Kluepfel, D., Bagli, J. F., Baker, H., Charest, M.-P., KUDELSKI, A., SEHGAL, S. N., & Vézina, C. (1972) · The Journal of Antibiotics · doi:10.7164/antibiotics.25.109 · Cited by 201 · see citing works

Sphingosine 1-phosphate receptor modulation suppresses pathogenic astrocyte activation and chronic progressive CNS inflammation

Rothhammer, V., Kenison, J. E., Tjon, E. C., Takenaka, M. C., de Lima, K. A., Borucki, D. M., Chao, C., Wilz, A., Blain, M., Healy, L. M., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1615413114 · Cited by 196 · see citing works

Activation of a High Affinity Gi Protein-coupled Plasma Membrane Receptor by Sphingosine-1-phosphate

van Koppen, C. J., zu Heringdorf, D. M., Laser, K. T., Zhang, C., Jakobs, K. H., Bünemann, M., & Pott, L. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.4.2082 · Cited by 192 · see citing works

Insights into autotaxin: how to produce and present a lipid mediator

Moolenaar, W. H., & Perrakis, A. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3188 · Cited by 190 · see citing works

Identification of a Molecular Target of Psychosine and Its Role in Globoid Cell Formation

Im, D., Heise, C. E., Nguyen, T., O’Dowd, B. F., & Lynch, K. R. (2001) · The Journal of Cell Biology · doi:10.1083/jcb.153.2.429 · Cited by 190 · see citing works

Lysophospholipid receptors in drug discovery

Kihara, Y., Mizuno, H., & Chun, J. J. M. (2014) · Experimental Cell Research · doi:10.1016/j.yexcr.2014.11.020 · Cited by 189 · see citing works

Long-term effects of fingolimod in multiple sclerosis

Kappos, L., O'Connor, P. W., Radue, E. W., Polman, C. H., Hohlfeld, R., Selmaj, K. W., Ritter, S., Schlosshauer, R., von Rosenstiel, P., Zhang-Auberson, L., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001462 · Cited by 188 · see citing works

A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya).

Chun, J. J. M., & Brinkmann, V. (2011) · PubMed · Cited by 177 · see citing works

Sphingosine-1-phosphate Lyase Deficiency Produces a Pro-inflammatory Response While Impairing Neutrophil Trafficking

Allende, M. L., Bektas, M., Lee, B. G., Bonifacino, E., Kang, J., Tuymetova, G., Chen, W., Saba, J. D., & Proia, R. L. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.171819 · Cited by 177 · see citing works

Molecular cloning of a high-affinity receptor for the growth factor-like lipid mediator lysophosphatidic acid from Xenopus oocytes

Guo, Z., Liliom, K., Fischer, D. J., Bathurst, I., Tomei, L., Kiefer, M. C., & Tigyi, G. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.25.14367 · Cited by 171 · see citing works

Regulation of Schwann Cell Morphology and Adhesion by Receptor-Mediated Lysophosphatidic Acid Signaling

Weiner, J. A., Fukushima, N., Contos, J. J. A., Scherer, S. S., & Chun, J. J. M. (2001) · Journal of Neuroscience · doi:10.1523/jneurosci.21-18-07069.2001 · Cited by 167 · see citing works

Central nervous system-directed effects of FTY720 (fingolimod)

Miron, V. E., Schubart, A., & Antel, J. P. (2008) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2008.06.031 · Cited by 163 · see citing works

Functional consequences of S1P receptor modulation in rat oligodendroglial lineage cells

Jung, C., Kim, H., Miron, V. E., Cook, S. P., Kennedy, T. E., Foster, C. A., Antel, J. P., & Soliven, B. C. (2007) · Glia · doi:10.1002/glia.20576 · Cited by 157 · see citing works

A growing family of receptor genes for lysophosphatidic acid (LPA) and other lysophospholipids (LPs)

Chun, J. J. M., Contos, J. J. A., & Munroe, D. G. (1999) · Cell Biochemistry and Biophysics · doi:10.1007/bf02738068 · Cited by 148 · see citing works

Assessing treatment outcomes in multiple sclerosis trials and in the clinical setting

Tur, C., Moccia, M., Barkhof, F., Chataway, J., Sastre‐Garriga, J., Thompson, A. J., & Ciccarelli, O. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.171 · Cited by 146 · see citing works

The Direct Effects of Fingolimod in the Central Nervous System: Implications for Relapsing Multiple Sclerosis

Hunter, S. F., Bowen, J. D., & Reder, A. T. (2015) · CNS Drugs · doi:10.1007/s40263-015-0297-0 · Cited by 144 · see citing works

FTY720 Rescue Therapy in the Dark Agouti Rat Model of Experimental Autoimmune Encephalomyelitis: Expression of Central Nervous System Genes and Reversal of Blood‐Brain‐Barrier Damage

Foster, C. A., Mechtcheriakova, D., Storch, M. K., Balatoni, B., Howard, L. M., Bornancin, F., Wlachos, A., Sobanov, J., Kinnunen, A., & Baumruker, T. (2008) · Brain Pathology · doi:10.1111/j.1750-3639.2008.00182.x · Cited by 143 · see citing works

Targeting blood-brain barrier sphingolipid signaling reduces basal P-glycoprotein activity and improves drug delivery to the brain

Cannon, R. E., Peart, J. C., Hawkins, B. T., Campos, C. R., & Miller, D. S. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1203534109 · Cited by 141 · see citing works

Incidence and Outcome of Progressive Multifocal Leukoencephalopathy over 20 Years of the Swiss HIV Cohort Study

Khanna, N., Elzi, L., Mueller, N. J., Garzoni, C., Cavassini, M. L., Fux, C. A., Vernazza, P., Bernasconi, E., Battegay, M., Hirsch, H. H., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/598335 · Cited by 141 · see citing works

Phosphorylated FTY720 promotes astrocyte migration through sphingosine‐1‐phosphate receptors

Müllershausen, F., Craveiro, L. M., Shin, Y., Cortés-Cros, M., Bassilana, F., Osinde, M., Wishart, W. L., Guerini, D., Thallmair, M., Schwab, M. E., et al. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04629.x · Cited by 140 · see citing works

Promising Pharmacological Directions in the World of Lysophosphatidic Acid Signaling

Lummis, N. C., & Chun, J. J. M. (2015) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2014.109 · Cited by 136 · see citing works

LPA4 regulates blood and lymphatic vessel formation during mouse embryogenesis

Sumida, H., Noguchi, K., Kihara, Y., Abe, M., Yanagida, K., Hamano, F., Sato, S., Tamaki, K., Morishita, Y., Kano, M. R., et al. (2010) · Blood · doi:10.1182/blood-2010-03-272443 · Cited by 135 · see citing works

Potent Immunosuppressants, 2-Alkyl-2-aminopropane-1,3-diols

Fujita, T., Hirose, R., Yoneta, M., Sasaki, S., Inoue, K., Kiuchi, M., Hirase, S., Chiba, K., Sakamoto, H., & Arita, M. (1996) · Journal of Medicinal Chemistry · doi:10.1021/jm960391l · Cited by 133 · see citing works

Targeted Deletion of LPA5 Identifies Novel Roles for Lysophosphatidic Acid Signaling in Development of Neuropathic Pain

Lin, M., Rivera, R. R., & Chun, J. J. M. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.330183 · Cited by 132 · see citing works

Structural insights into ligand recognition by the lysophosphatidic acid receptor LPA6

Taniguchi, R., Inoue, A., Sayama, M., Uwamizu, A., Yamashita, K., Hirata, K., Yoshida, M., Tanaka, Y., KATO, H. E., Nakada-Nakura, Y., et al. (2017) · Nature · doi:10.1038/nature23448 · Cited by 130 · see citing works

FTY720, a novel immunosuppressant possessing unique mechanisms. I. Prolongation of skin allograft survival and synergistic effect in combination with cyclosporine in rats.

Chiba, K., Hoshino, Y., Suzuki, T., Masubuchi, Y., Yanagawa, Y., Ohtsuki, M., Sasaki, S., & Fujita, T. (1996) · PubMed · Cited by 127 · see citing works

ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate receptor modulators and proteasome inhibitors)

Redelman‐Sidi, G., Michielin, O. A., Cervera, C., Ribi, C., Aguado, J. M., Fernández‐Ruiz, M., & Manuel, O. (2018) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2018.01.030 · Cited by 126 · see citing works

Glycerophospholipid regulation of modality-specific sensory axon guidance in the spinal cord

Guy, A. T., Nagatsuka, Y., Ooashi, N., Inoue, M., Nakata, A., Greimel, P., Inoue, A., Nabetani, T., Murayama, A., Ohta, K., et al. (2015) · Science · doi:10.1126/science.aab3516 · Cited by 121 · see citing works

A new immunosuppressant, FTY720, induces bcl‐2‐associated apoptotic cell death in human lymphocytes

Suzuki, S., LI, X. ‐., Enosawa, S., & Shinomiya, T. (1996) · Immunology · doi:10.1046/j.1365-2567.1996.d01-777.x · Cited by 118 · see citing works

Lysophosphatidic acid targets vascular and oncogenic pathways via RAGE signaling

Rai, V., Touré, F., Chitayat, S., Pei, R., Song, F., Li, Q., Zhang, J., Rosario, R., Ramasamy, R., Chazin, W., et al. (2012) · The Journal of Experimental Medicine · doi:10.1084/jem.20120873 · Cited by 117 · see citing works

FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats, III. Increase in frequency of CD62L‐positive T cells in Peyer’s patches by FTY720‐induced lymphocyte homing

YANAGAWA, Masubuchi, & Chiba (1998) · Immunology · doi:10.1046/j.1365-2567.1998.00639.x · Cited by 115 · see citing works

Randomized Controlled Trial of FTY720 Versus MMF in De Novo Renal Transplantation

Junior, H. T. S., Pescovitz, M. D., Cibrik, D. M., Rees, M. A., Mulgaonkar, S. P., Kahan, B. D., Gugliuzza, K., Rajagopalan, P. R., Esmeraldo, R. D. M., Lord, H., et al. (2006) · Transplantation · doi:10.1097/01.tp.0000251718.95622.b3 · Cited by 107 · see citing works

Embryonic brain expression analysis of lysophospholipid receptor genes suggests roles for s1p 1 in neurogenesis and s1p 1–3 in angiogenesis

McGiffert, C., Contos, J. J. A., Friedman, B., & Chun, J. J. M. (2002) · FEBS Letters · doi:10.1016/s0014-5793(02)03404-x · Cited by 106 · see citing works

Sphingosine 1-phosphate receptor 3 and RhoA signaling mediate inflammatory gene expression in astrocytes

Dusaban, S. S., Chun, J., Rosen, H., Purcell, N. H., & Brown, J. H. (2017) · Journal of Neuroinflammation · doi:10.1186/s12974-017-0882-x · Cited by 106 · see citing works

T cell necessity in the pathogenesis of experimental autoimmune encephalomyelitis in mice

Bernard, C. C. A., Leydon, J., & Mackay, I. R. (1976) · European Journal of Immunology · doi:10.1002/eji.1830060912 · Cited by 104 · see citing works

Expression and Function of Lysophosphatidic Acid Receptors in Cultured Rodent Microglial Cells

Möller, T., Contos, J. J. A., Musante, D. B., Chun, J. J. M., & Ransom, B. R. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m102691200 · Cited by 104 · see citing works

The neurobiology of sphingosine 1-phosphate signaling and sphingosine 1-phosphate receptor modulators

Soliven, B. C., Miron, V. E., & Chun, J. J. M. (2011) · Neurology · doi:10.1212/wnl.0b013e31820d9507 · Cited by 103 · see citing works

Early brain pseudoatrophy while on natalizumab therapy is due to white matter volume changes

Vidal‐Jordana, Á., Sastre‐Garriga, J., Miralles, F. C. P., Tur, C., Tintoré, M., Horga, A., Auger, C., Río, J., Nos, C., Edo, M. C., et al. (2013) · Multiple Sclerosis Journal · doi:10.1177/1352458512473190 · Cited by 102 · see citing works

FTY720 (fingolimod) in renal transplantation

Budde, K., Schütz, M., Glander, P., Peters, H., Waiser, J., Liefeldt, L., Neumayer, H., & Böhler, T. (2006) · Clinical Transplantation · doi:10.1111/j.1399-0012.2006.00596.x · Cited by 101 · see citing works

Simple compounds, 2-alkyl-2-amino-1,3-propanediols have potent immunosuppressive activity

Fujita, T., Yoneta, M., Hirose, R., Sasaki, S., Inoue, K., Kiuchi, M., Hirase, S., Adachi, K., Arita, M., & Chiba, K. (1995) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/0960-894x(95)00126-e · Cited by 101 · see citing works

Multiple‐Dose FTY720: Tolerability, Pharmacokinetics, and Lymphocyte Responses in Healthy Subjects

Kovarik, J. M., Schmouder, R., Barilla, D., Rivière, G., Wang, Y., & Hunt, T. L. (2004) · The Journal of Clinical Pharmacology · doi:10.1177/0091270004264165 · Cited by 95 · see citing works

Infections in Patients Receiving Multiple Sclerosis Disease-Modifying Therapies

Grebenciucova, E., & Pruitt, A. A. (2017) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-017-0800-8 · Cited by 94 · see citing works

Pharmacologically active acidic phospholipids and glycolipids

Vogt, W. (1963) · Biochemical Pharmacology · doi:10.1016/0006-2952(63)90074-1 · Cited by 87 · see citing works

Differential projections of ciliated and microvillous olfactory receptor cells in the catfish,Ictalurus punctatus

Morita, Y., & Finger, T. E. (1998) · The Journal of Comparative Neurology · doi:10.1002/(sici)1096-9861(19980907)398:4 · Cited by 87 · see citing works

Fingolimod protects cultured cortical neurons against excitotoxic death

Menna, L. D., Molinaro, G., di Nuzzo, L., Riozzi, B., Zappulla, C., Pozzilli, C., Turrini, R., Caraci, F., Copani, A., Battaglia, G., et al. (2012) · Pharmacological Research · doi:10.1016/j.phrs.2012.10.004 · Cited by 84 · see citing works

Induction of selective cell death targeting on mature T-lymphocytes in rats by a novel immunosuppressant, FTY720

Enosawa, S., Suzuki, S., Kakefuda, T., Li, X., & Amemiya, H. (1996) · Immunopharmacology · doi:10.1016/0162-3109(96)00132-4 · Cited by 82 · see citing works

Lysophospholipid Receptors: Implications for Neural Signaling

Chun, J. J. M. (1999) · Critical Reviews in Neurobiology · doi:10.1615/critrevneurobiol.v13.i2.20 · Cited by 82 · see citing works

Lysophosphatidic Acid Stimulates Neurotransmitter-Like Conductance Changes that Precede GABA and l-Glutamate in Early, Presumptive Cortical Neuroblasts

Dubin, A. E., Bahnson, T. D., Weiner, J. A., Fukushima, N., & Chun, J. J. M. (1999) · Journal of Neuroscience · doi:10.1523/jneurosci.19-04-01371.1999 · Cited by 79 · see citing works

T Cell Requirement for Experimental Allergic Encephalomyelitis Induction in the Rat

Ortíz-Ortíz, L., Nakamura, R. M., & Weigle, W. O. (1976) · The Journal of Immunology · doi:10.4049/jimmunol.117.2.576 · Cited by 73 · see citing works

Fungal metabolites. Part 12. Potent immunosuppressant, 14-deoxomyriocin, (2S,3R,4R)-(E)-2-amino-3,4-dihydroxy-2-hydroxymethyleicos-6-enoic acid and structure-activity relationships of myriocin derivatives.

Fujita, T., Inoue, K., Yamamoto, S., Ikumoto, T., Sasaki, S., TOYAMA, R., Chiba, K., Hoshino, Y., & Okumoto, T. (1994) · The Journal of Antibiotics · doi:10.7164/antibiotics.47.216 · Cited by 73 · see citing works

Lysophosphatidic acid in neural signaling

Ye, X., Fukushima, N., Kingsbury, M. A., & Chun, J. J. M. (2002) · Neuroreport · doi:10.1097/00001756-200212030-00002 · Cited by 72 · see citing works

Antihypertensive effect of an isolated phospholipid

Sen, S., Smeby, R., & Bumpus, F. M. (1968) · American Journal of Physiology-Legacy Content · doi:10.1152/ajplegacy.1968.214.2.337 · Cited by 67 · see citing works

Effect of Fingolimod on Brain Volume Loss in Patients with Multiple Sclerosis

Stefano, N. D., Silva, D. G., & Barnett, M. H. (2017) · CNS Drugs · doi:10.1007/s40263-017-0415-2 · Cited by 66 · see citing works

FTY720 Versus Mycophenolate Mofetil in De Novo Renal Transplantation: Six-Month Results of a Double-Blind Study

Junior, H. T. S., Szakály, P., SHOKER, A. S., Sommerer, C., Yoshimura, N., Schena, F. P., Cremer, M., Hmissi, A., Mayer, H. W., & Lang, P. (2007) · Transplantation · doi:10.1097/01.tp.0000281385.26500.3b · Cited by 65 · see citing works

Differential responses of human microglia and blood-derived myeloid cells to FTY720

Durafourt, B. A., Lambert, C., Johnson, T., Blain, M., Bar‐Or, A., & Antel, J. P. (2010) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2010.08.006 · Cited by 63 · see citing works

Differential effects of fingolimod on B-cell populations in multiple sclerosis

Nakamura, M., Matsuoka, T., Chihara, N., Miyake, S., Sato, W., Araki, M., Okamoto, T., Lin, Y., Ogawa, M., Murata, M., et al. (2014) · Multiple Sclerosis Journal · doi:10.1177/1352458514523496 · Cited by 59 · see citing works

Synthesis and biological evaluation of 2,2-disubstituted 2-aminoethanols: analogues of FTY720

Kiuchi, M., Adachi, K., Kohara, T., Teshima, K., Masubuchi, Y., Mishina, T., & Fujita, T. (1998) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(97)10188-3 · Cited by 57 · see citing works

Metabolism of Sphingosine Bases, XIII. Enzymatic Synthesis of 1-Phosphate Esters of 4t-Sphingenine (Sphingosine), Sphinganine (Dihydrosphingosine), 4-Hydroxysphinganine (Phytosphingosine) and 3-Dehydrosphinganine by Erythrocytes

Stoffel, W., Assmann, G., & Binczek, E. (1970) · Hoppe-Seyler´s Zeitschrift für physiologische Chemie · doi:10.1515/bchm2.1970.351.1.635 · Cited by 57 · see citing works

Evidence that FTY720 induces T cell apoptosis in vivo

Nagahara, Y., Enosawa, S., Ikekita, M., Suzuki, S., & Shinomiya, T. (2000) · Immunopharmacology · doi:10.1016/s0162-3109(00)00181-8 · Cited by 56 · see citing works

Characterization of a Receptor Subtype-Selective Lysophosphatidic Acid Mimetic

Hooks, S. B., Ragan, S. P., Hopper, D. W., Hönemann, C., Durieux, M. E., Macdonald, T. L., & Lynch, K. R. (1998) · Molecular Pharmacology · doi:10.1124/mol.53.2.188 · Cited by 52 · see citing works

Lysophosphatidic acid potentiates the thrombin-induced production of arachidonate metabolites in platelets.

Lapetina, E. G., Billah, M. M., & Cuatrecasas, P. (1981) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)43219-x · Cited by 50 · see citing works

Prevention of graft rejection and graft-versus-host reaction by a novel immunosuppressant, FTY 720, in rat small bowel transplantation

Mitsusada, M., Suzuki, S., Kobayashi, E., Enosawa, S., Kakefuda, T., & Miyata, M. (1997) · Transplant International · doi:10.1007/s001470050068 · Cited by 50 · see citing works

Sphingosine 1-phosphate enhances the excitability of rat sensory neurons through activation of sphingosine 1-phosphate receptors 1 and/or 3

Li, C., Li, J.-N., Kays, J. S., Guerrero, M. A., & Nicol, G. D. (2015) · Journal of Neuroinflammation · doi:10.1186/s12974-015-0286-8 · Cited by 50 · see citing works

Neurobiology of Receptor‐Mediated Lysophospholipid Signaling: From the First Lysophospholipid Receptor to Roles in Nervous System Function and Development

Chun, J. J. M., Weiner, J. A., Fukushima, N., Contos, J. J. A., ZHANG, G., Kimura, Y., Dubin, A. E., Ishii, I., Hecht, J. H., AKITA, C., et al. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06543.x · Cited by 48 · see citing works

FTY720, a novel immunosuppressant possessing unique mechanisms. III. Synergistic prolongation of canine renal allograft survival in combination with cyclosporine A.

Kawaguchi, T., Hoshino, Y., Rahman, F., Amano, Y., HIGASHI, H., Kataoka, H., Ohtsuki, M., Teshima, K., Chiba, K., Kakefuda, T., et al. (1996) · PubMed · Cited by 47 · see citing works

FTY720, a novel immunosuppressant, induces sequestration of circulating lymphocytes by acceleration of lymphocyte homing

Chiba, K., Yanagawa, Y., Kataoka, H., Kawaguchi, T., Ohtsuki, M., & Hoshino, Y. (1999) · Transplantation Proceedings · doi:10.1016/s0041-1345(98)01975-7 · Cited by 47 · see citing works

Effect of Fingolimod on Neural Stem Cells: A Novel Mechanism and Broadened Application for Neural Repair

Zhang, Y., Li, X., Ćirić, B., Ma, C., Gran, B., Rostami, A. M., & Zhang, G. (2016) · Molecular Therapy · doi:10.1016/j.ymthe.2016.12.008 · Cited by 42 · see citing works

Regulation of T‐cell apoptosis: a mixed lymphocyte reaction model

O'Flaherty, E., Wong, W. ‐., Pettit, S. J., Seymour, K., Ali, S., & Kirby, J. A. (2000) · Immunology · doi:10.1046/j.1365-2567.2000.00048.x · Cited by 41 · see citing works

The FTY720 Story

Napoli, K. L. (2000) · Therapeutic Drug Monitoring · doi:10.1097/00007691-200002000-00010 · Cited by 41 · see citing works

Thermozymocidin new antifungal antibiotic from a thermophilic eumycete

Craveri, R., Manachini, P. L., & Aragozzini, F. (1972) · Cellular and Molecular Life Sciences · doi:10.1007/bf01923181 · Cited by 39 · see citing works

Lysophosphatidic acid receptors LPA 4 and LPA 6 differentially promote lymphocyte transmigration across high endothelial venules in lymph nodes

Hata, E., Sasaki, N., Takeda, A., Tohya, K., Umemoto, E., Akahoshi, N., Ishii, S., Bando, K., Abe, T., Kano, K., et al. (2015) · International Immunology · doi:10.1093/intimm/dxv072 · Cited by 36 · see citing works

Roles for lysophospholipid S1P receptors in multiple sclerosis

Noguchi, K., & Chun, J. J. M. (2010) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409238.2010.522975 · Cited by 35 · see citing works

Fingolimod effect on brain volume loss independently contributes to its effect on disability

Sormani, M. P., Stefano, N. D., Francis, G. S., Sprenger, T., Chin, P., Radue, E. W., & Kappos, L. (2015) · Multiple Sclerosis Journal · doi:10.1177/1352458515569099 · Cited by 33 · see citing works

FTY720, a novel immunosuppressant, prolongs rat skin allograft survival by decreasing T-Cell infiltration into grafts

Yanagawa, Y., Hoshino, Y., Kataoka, H., Kawaguchi, T., Ohtsuki, M., Sugahara, K., & Chiba, K. (1999) · Transplantation Proceedings · doi:10.1016/s0041-1345(98)01974-5 · Cited by 33 · see citing works

Pharmakologisch wirksame lipoidlösliche säuren in hirnextrakten: Isolierung von lysophosphatidsäure und gangliosid

Kirschner, H., & Vogt, W. (1961) · Biochemical Pharmacology · doi:10.1016/0006-2952(61)90005-3 · Cited by 30 · see citing works

Lysophospholipid Receptors: Signaling and Biochemistry

Chun, J. J. M. (2013) · Cited by 29 · see citing works

An immunosuppressive regimen using FTY720 combined with cyclosporin in canine kidney transplantation

Suzuki, S., Kakefuda, T., Amemiya, H., Chiba, K., Hoshino, Y., Kawaguchi, T., Kataoka, H., & Rahman, F. (1998) · Transplant International · doi:10.1007/s001470050111 · Cited by 29 · see citing works

Induction of lymphocyte apoptosis and prolongation of allograft survival by FTY720.

Suzuki, S., Li, X. K., Shinomiya, T., Enosawa, S., Kakefuda, T., Mitsusada, M., Amemiya, H., Takahara, S., Amari, M., Naoe, S., et al. (1996) · PubMed · Cited by 24 · see citing works

Lysophosphatidic acid receptors LPA4 and LPA6 differentially promote lymphocyte transmigration across high endothelial venules in lymph nodes

秦, 枝. (2016) · Cited by 24 · see citing works

Lipid bilayer molecular dynamics study of lipid-derived agonists of the putative cannabinoid receptor, GPR55

Kotsikorou, E., Lynch, D. L., Abood, M. E., & Reggio, P. H. (2010) · Chemistry and Physics of Lipids · doi:10.1016/j.chemphyslip.2010.12.003 · Cited by 23 · see citing works

Reconstitution of a protein into lipid vesicles using natural detergents

Christiansen, K., & Carlsen, J. (1983) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(83)90297-3 · Cited by 20 · see citing works

Metabolism of Sphingosine Bases, X. Degradation of [1-14C]Dihydrosphingosine (Sphinganine), [1-14C]2-Amino-1,3-dihydroxyheptane and [1-14C]Dihydrosphingosine phosphate im Rat Liver

Stoffel, W., Sticht, G., & KIM, D. L. (1969) · Hoppe-Seyler´s Zeitschrift für physiologische Chemie · doi:10.1515/bchm2.1969.350.1.63 · Cited by 20 · see citing works

Efectos del fingolimod en el sistema nervioso central

Cruz, V. T., & Fonseca, J. (2014) · Revista de Neurología · doi:10.33588/rn.5903.2013556 · Cited by 17 · see citing works

The enzymic hydrolysis of phosphatides: Lysolecithin.

King, E. J., & Dolan, M. (1933) · PubMed · Cited by 15 · see citing works

Efficacy of Siponimod in Secondary Progressive Multiple Sclerosis: Results of the Phase 3 Study (CT.002)

Kappos, L., Bar‐Or, A., Cree, B., Fox, R. J., Giovannoni, G., Gold, R., Vermersch, P., Arnould, S., Sidorenko, T., Wolf, C., et al. (2017) · Neurology · doi:10.1212/wnl.88.16_supplement.ct.002 · Cited by 14 · see citing works

New drugs and personalized medicine for multiple sclerosis

Matthews, P. M. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.200 · Cited by 11 · see citing works

Mycophenolic acid and intravenous immunoglobulin exert an additive effect on cell proliferation and apoptosis in the mixed lymphocyte reaction

Sharma, K. G., Radha, R., Pao, A., Amet, N., Baden, L., Jordan, S. C., & Toyoda, M. (2010) · Transplant Immunology · doi:10.1016/j.trim.2010.04.009 · Cited by 8 · see citing works

Rescue effect of FTY720 on acute renal rejection in dogs

Yuzawa, K., Otsuka, M., Taniguchi, H., Takada, Y., Sakurayama, N., Jinzenji, Y., Suzuki, S., & Fukao, K. (1999) · Transplantation Proceedings · doi:10.1016/s0041-1345(98)01811-9 · Cited by 8 · see citing works

ChemInform Abstract: Fungal Metabolites. Part 12. Potent Immunosuppressant, 14‐ Deoxomyriocin, (2S,3R,4R)‐(E)‐2‐Amino‐3,4‐dihydroxy‐2‐ hydroxymethyleicos‐6‐enoic acid and Structure‐Activity Relationships of Myriocin Derivatives.

Fujita, T., INOUE, K., Yamamoto, S., Ikumoto, T., Sasaki, S., TOYAMA, R., Yoneta, M., Chiba, K., Hoshino, Y., & Okumoto, T. (1994) · ChemInform · doi:10.1002/chin.199432254 · Cited by 7 · see citing works

An Effect of FTY720 on Acute Rejection in Canine Renal Transplantation

Yuzawa, K., Otsuka, M., Taniguchi, H., Takada, Y., Sakurayama, N., Jinzenji, Y., Suzuki, S., & Fukao, K. (1998) · Transplantation Proceedings · doi:10.1016/s0041-1345(98)00144-4 · Cited by 5 · see citing works

[NMO spectrum disorders and anti AQP4 antibody].

Takai, Y., Misu, T., Takahashi, T., Nakashima, I., & Fujihara, K. (2013) · PubMed · Cited by 3 · see citing works

[Immunosuppressive agent FTY720].

Kobayakawa, T., & Chiba, K. (2000) · PubMed · Cited by 2 · see citing works

Atopic dermatitis: an expanding therapeutic pipeline for a complex disease

Bieber, T. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00266-6 · Cited by 623 · see citing works

Sphingosine 1-phosphate Receptor Modulator Therapy for Multiple Sclerosis: Differential Downstream Receptor Signalling and Clinical Profile Effects

Chun, J. J. M., Giovannoni, G., & Hunter, S. F. (2020) · Drugs · doi:10.1007/s40265-020-01431-8 · Cited by 156 · see citing works

Autoreactive lymphocytes in multiple sclerosis: Pathogenesis and treatment target

Liu, R., Du, S., Zhao, L., Jain, S., Sahay, K., Rizvanov, A. A., Lezhnyova, V., Хайбуллин, Т. И., Martynova, E. V., Khaiboullina, S. F., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.996469 · Cited by 153 · see citing works

Sphingolipids as prognostic biomarkers of neurodegeneration, neuroinflammation, and psychiatric diseases and their emerging role in lipidomic investigation methods

van Kruining, D., Luo, Q., van Echten‐Deckert, G., Mielke, M. M., Bowman, A. P., Ellis, S. R., Oliveira, T. G., & Martínez‐Martínez, P. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.04.009 · Cited by 136 · see citing works

Finding a way out: S1P signaling and immune cell migration

Baeyens, A. A. L., & Schwab, S. R. (2020) · Annual Review of Immunology · doi:10.1146/annurev-immunol-081519-083952 · Cited by 123 · see citing works

T Cell Response in Ischemic Stroke: From Mechanisms to Translational Insights

Zhang, D., Ren, J., Luo, Y., He, Q., Zhao, R., Chang, J., Yang, Y., & Guo, Z. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.707972 · Cited by 101 · see citing works

Structural basis of sphingosine-1-phosphate receptor 1 activation and biased agonism

Xu, Z., Ikuta, T., Kawakami, K., Kise, R., Yu, Q., Xia, R., Sun, M., Zhang, A., Guo, C., Cai, X., et al. (2021) · Nature Chemical Biology · doi:10.1038/s41589-021-00930-3 · Cited by 97 · see citing works

LPA 2 Contributes to Vascular Endothelium Homeostasis and Cardiac Remodeling After Myocardial Infarction

Pei, J., Cai, L., Wang, F., Xu, C., Pei, S., Guo, H., Sun, X., Chun, J. J. M., Cong, X., Zhu, W., et al. (2022) · Circulation Research · doi:10.1161/circresaha.122.321036 · Cited by 72 · see citing works

Serum Exosome MicroRNAs Predict Multiple Sclerosis Disease Activity after Fingolimod Treatment

Ebrahimkhani, S., Beadnall, H. N., Wang, C., Suter, C. M., Barnett, M. H., Buckland, M. E., & Vafaee, F. (2019) · Molecular Neurobiology · doi:10.1007/s12035-019-01792-6 · Cited by 72 · see citing works

A Functionally Defined In Vivo Astrocyte Population Identified by c-Fos Activation in a Mouse Model of Multiple Sclerosis Modulated by S1P Signaling: Immediate-Early Astrocytes (ieAstrocytes)

Groves, A., Kihara, Y., Jonnalagadda, D., Rivera, R. R., Kennedy, G., Mayford, M. R., & Chun, J. J. M. (2018) · eNeuro · doi:10.1523/eneuro.0239-18.2018 · Cited by 52 · see citing works

Emerging Role of Compartmentalized G Protein-Coupled Receptor Signaling in the Cardiovascular Field

Plouffe, B., Thomsen, A. R. B., & Irannejad, R. (2020) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00006 · Cited by 46 · see citing works

Dynamic trafficking patterns of IL-17-producing γδ T cells are linked to the recurrence of skin inflammation in psoriasis-like dermatitis

Liu, N., Qin, H., Cai, Y., Li, X., Wang, L., Xu, Q., Xue, F., Chen, L., Ding, C., Hu, X., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104136 · Cited by 50 · see citing works

The Two Sides of Siponimod: Evidence for Brain and Immune Mechanisms in Multiple Sclerosis

COHAN, S. L., Benedict, R. H. B., Cree, B., DeLuca, J., Hua, L. H., & Chun, J. J. M. (2022) · CNS Drugs · doi:10.1007/s40263-022-00927-z · Cited by 44 · see citing works

‘Crystal’ Clear? Lysophospholipid Receptor Structure Insights and Controversies

Blaho, V. A., & Chun, J. J. M. (2018) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2018.08.006 · Cited by 41 · see citing works

Screening of FDA-Approved Drugs Using a 384-Well Plate-Based Biofilm Platform: The Case of Fingolimod

Gilbert-Girard, S., Savijoki, K., Yli‐Kauhaluoma, J. T., & Fallarero, A. (2020) · Microorganisms · doi:10.3390/microorganisms8111834 · Cited by 38 · see citing works

Sphingosine 1-Phosphate as Essential Signaling Molecule in Inflammatory Skin Diseases

Kleuser, B., & Bäumer, W. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021456 · Cited by 40 · see citing works

Multiple Sclerosis: Therapeutic Strategies on the Horizon

Manjunatha, R. T., Habib, S., Sangaraju, S. L., Yepez, D., & Grandes, X. A. (2022) · Cureus · doi:10.7759/cureus.24895 · Cited by 38 · see citing works

Cytokine-Induced and Stretch-Induced Sphingosine 1-Phosphate Production by Enthesis Cells Could Favor Abnormal Ossification in Spondyloarthritis

Jamal, A. E., Briolay, A., Mebarek, S., Goff, B. L., Blanchard, F., Magne, D., Brizuela, L., & Bougault, C. (2019) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3844 · Cited by 35 · see citing works

Molecular Mechanisms in the Genesis of Seizures and Epilepsy Associated With Viral Infection

Löscher, W., & Howe, C. L. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.870868 · Cited by 33 · see citing works

FTY720 in CNS injuries: Molecular mechanisms and therapeutic potential

Zhang, L., & Wang, H. (2020) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2020.08.013 · Cited by 34 · see citing works

Druggable Lipid GPCRs: Past, Present, and Prospects

Mizuno, H., & Kihara, Y. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-50621-6_10 · Cited by 31 · see citing works

Siponimod exerts neuroprotective effects on the retina and higher visual pathway through neuronal S1PR1 in experimental glaucoma

Basavarajappa, D. K., Gupta, V., Chitranshi, N., Wall, R. V., Rajput, R., Pushpitha, K., Sharma, S., Mirzaei, M., Klistorner, A. I., & Graham, S. L. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.344952 · Cited by 28 · see citing works

Neuroinflammation in Autoimmune Disease and Primary Brain Tumors: The Quest for Striking the Right Balance

Mitchell, D. K., Shireman, J. M., Potchanant, E. A. S., Lara-Velazquez, M. A., & Dey, M. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.716947 · Cited by 27 · see citing works

A Novel Agonist of the Type 1 Lysophosphatidic Acid Receptor (LPA1), UCM-05194, Shows Efficacy in Neuropathic Pain Amelioration

González-Gil, I., Zian, D., Vázquez‐Villa, H., Hernández‐Torres, G., Martínez, R. F., Khiar‐Fernández, N., Rivera, R. R., Kihara, Y., Devesa, I., Mathivanan, S., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01287 · Cited by 27 · see citing works

Single-Nucleus RNA-seq of Normal-Appearing Brain Regions in Relapsing-Remitting vs. secondary Progressive Multiple Sclerosis: implications for the Efficacy of fingolimod

Kihara, Y., Zhu, Y., Jonnalagadda, D., Romanow, W., Palmer, C., Siddoway, B., Rivera, R., Dutta, R., Trapp, B. D., & Chun, J. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2022.918041 · Cited by 26 · see citing works

Lysophospholipid G protein-coupled receptor binding parameters as determined by backscattering interferometry

Mizuno, H., Kihara, Y., Kussrow, A. K., Chen, A., Ray, M., Rivera, R. R., Bornhop, D. J., & Chun, J. J. M. (2018) · Journal of Lipid Research · doi:10.1194/jlr.d089938 · Cited by 25 · see citing works

Molecular and neuroimmune pharmacology of S1P receptor modulators and other disease-modifying therapies for multiple sclerosis

Kihara, Y., & Chun, J. J. M. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108432 · Cited by 24 · see citing works

Ponesimod inhibits astrocyte-mediated neuroinflammation and protects against cingulum demyelination via S1P1-selective modulation

Kihara, Y., Jonnalagadda, D., Zhu, Y., Ray, M., Ngo, T., Palmer, C. R., Rivera, R., & Chun, J. (2022) · The FASEB Journal · doi:10.1096/fj.202101531r · Cited by 18 · see citing works

From the Molecular Mechanism to Pre-clinical Results: Anti-epileptic Effects of Fingolimod

Paudel, Y. N., Angelopoulou, E., Piperi, C., Gnatkovsky, V., Othman, I., & Shaikh, M. F. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200420125017 · Cited by 22 · see citing works

Clinical Potential of Immunotherapies in Subarachnoid Hemorrhage Treatment: Mechanistic Dissection of Innate and Adaptive Immune Responses

Zhang, A., Liu, Y., Wang, X., Xu, H., Fang, C., Yuan, L., Wang, K., Zheng, J., Qi, Y., Chen, S., et al. (2023) · Aging and Disease · doi:10.14336/ad.2023.0126 · Cited by 22 · see citing works

Gene Therapy Approaches in an Autoimmune Demyelinating Disease: Multiple Sclerosis

Islam, M. A., Kundu, S., & Hassan, R. (2020) · Current Gene Therapy · doi:10.2174/1566523220666200306092556 · Cited by 21 · see citing works

Hotair and Malat1 Long Noncoding RNAs Regulate Bdnf Expression and Oligodendrocyte Precursor Cell Differentiation

Khani‐Habibabadi, F., Zare, L., Sahraian, M. A., Javan, M., & Behmanesh, M. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-02844-0 · Cited by 21 · see citing works

Unlabeled lysophosphatidic acid receptor binding in free solution as determined by a compensated interferometric reader

Ray, M., Nagai, K., Kihara, Y., Kussrow, A. K., Kammer, M. N., Frantz, A., Bornhop, D. J., & Chun, J. J. M. (2020) · Journal of Lipid Research · doi:10.1194/jlr.d120000880 · Cited by 21 · see citing works

Conditional Lpar1 gene targeting identifies cell types mediating neuropathic pain

Rivera, R. R., Lin, M., Bornhop, E. C., & Chun, J. J. M. (2020) · The FASEB Journal · doi:10.1096/fj.202000317r · Cited by 21 · see citing works

A Soluble Epoxide Hydrolase Inhibitor, 1-trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl) Urea, Ameliorates Experimental Autoimmune Encephalomyelitis

Jonnalagadda, D., Wan, D., Chun, J. J. M., Hammock, B. D., & Kihara, Y. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094650 · Cited by 20 · see citing works

Mysterious sphingolipids: metabolic interrelationships at the center of pathophysiology

Jamjoum, R., Majumder, S., Issleny, B. M., & Stiban, J. (2024) · Frontiers in Physiology · doi:10.3389/fphys.2023.1229108 · Cited by 20 · see citing works

Repurposing MS immunotherapies for CIDP and other autoimmune neuropathies: unfulfilled promise or efficient strategy?

Kohle, F., Dalakas, M. C., & Lehmann, H. C. (2023) · Therapeutic Advances in Neurological Disorders · doi:10.1177/17562864221137129 · Cited by 17 · see citing works

FTY720 requires vitamin B12-TCN2-CD320 signaling in astrocytes to reduce disease in an animal model of multiple sclerosis

Jonnalagadda, D., Kihara, Y., Groves, A., Ray, M., Saha, A., Ellington, C., Lee, H., Furihata, T., Yokomizo, T., Quadros, E. V., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113545 · Cited by 17 · see citing works

Imaging the Bone-Immune Cell Interaction in Bone Destruction

Hasegawa, T., Kikuta, J., & Ishii, M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00596 · Cited by 17 · see citing works

Antidepressant Sertraline Is a Broad-Spectrum Inhibitor of Enteroviruses Targeting Viral Entry through Neutralization of Endolysosomal Acidification

Tseng, K.-C., Hsu, B.-Y., Ling, P., Lu, W., Lin, C., & Kung, S. (2022) · Viruses · doi:10.3390/v14010109 · Cited by 17 · see citing works

The bioactive sphingolipid playbook. A primer for the uninitiated as well as sphingolipidologists

Hannun, Y. A., Merrill, A. H., & Luberto, C. (2025) · Journal of Lipid Research · doi:10.1016/j.jlr.2025.100813 · Cited by 16 · see citing works

Deciphering the role of sphingosine 1‐phosphate in central nervous system myelination and repair

Binish, F., & Xiao, J. (2024) · Journal of Neurochemistry · doi:10.1111/jnc.16228 · Cited by 15 · see citing works

Treatment of multiple sclerosis in children: A brief overview

Nicotera, A. G., Spoto, G., Saia, M. C., Midiri, M., Turriziani, L., Amore, G., & Rosa, G. D. (2022) · Clinical Immunology · doi:10.1016/j.clim.2022.108947 · Cited by 15 · see citing works

Chronic Intermittent Hypoxia‐Induced Neural Injury: Pathophysiology, Neurodegenerative Implications, and Therapeutic Insights

Jia, N., Yao, M., Zhu, C., He, M., Zhu, H., Chen, Z., Huang, H., & Chen, Q. (2025) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.70384 · Cited by 14 · see citing works

The relationship between increased levels of microbiota-derived lipopolysaccharide in obesity and the pathophysiology of neurodegenerative diseases

Mehboodi, M., Namdari, M. P., Abdollahi, Z., Mobarezi, Z., Kiani, M., Chamani, F., Khanbabaie, H., Rabiei, S., Maleki, M. H., Sanati, H., et al. (2025) · Microbial Pathogenesis · doi:10.1016/j.micpath.2025.107905 · Cited by 14 · see citing works

Current therapies for neurological disorders and their limitations

Rezaei, S., Morshedi, K., Shafabakhsh, R., & Mahjoubin‐Tehran, M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-824467-8.00009-7 · Cited by 14 · see citing works

Chemoselective Esterification of Natural and Prebiotic 1,2-Amino Alcohol Amphiphiles in Water

Bhattacharya, A., Tanwar, L., Fracassi, A., Brea, R. J., Salvador‐Castell, M., Khanal, S., Sinha, S. K., & Devaraj, N. K. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.3c12038 · Cited by 13 · see citing works

Inhibition of acid or neutral sphingomyelinases differentially impacts RNA and protein cargo sorting to extracellular vesicles

Padilla, J.-C. A., Barutcu, S., Boulais, J., da Silva, J. C., Chen, Y., Syed, E. U., Kwon, E., & Lécuyer, É. (2025) · iScience · doi:10.1016/j.isci.2025.112440 · Cited by 13 · see citing works

Zonation and ligand and dose dependence of sphingosine 1-phosphate receptor-1 signalling in blood and lymphatic vasculature

Gaudio, I. D., Nitzsche, A., Boyé, K., Bonnin, P., Poulet, M., Nguyen, Q. T., Couty, L., Ha, H. T. T., Nguyen, D. T., Cazenave‐Gassiot, A., et al. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvae168 · Cited by 13 · see citing works

Postnatal deletion of Spns2 prevents neuroinflammation without compromising blood vascular functions

Hasan, Z., Nguyen, Q. T., Lam, B. W. S., Wong, J. H., Wong, C. C. Y., Tan, C. K. H., Yu, J., Thiam, C. H., Zhang, Y., Angeli, V., et al. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04573-y · Cited by 13 · see citing works

Role of Sphingosylphosphorylcholine in Tumor and Tumor Microenvironment

Park, M. K., & Lee, C. H. (2019) · Cancers · doi:10.3390/cancers11111696 · Cited by 13 · see citing works

Immune System and Brain/Intestinal Barrier Functions in Psychiatric Diseases: Is Sphingosine-1-Phosphate at the Helm?

Martín‐Hernández, D., Muñoz‐López, M., Tendilla‐Beltrán, H., Caso, J. R., García‐Bueno, B., Menchen, L. A., & Leza, J. C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241612634 · Cited by 12 · see citing works

Preclinical and Clinical Evidence for the Involvement of Sphingosine 1-Phosphate Signaling in the Pathophysiology of Vascular Cognitive Impairment

Chua, X. Y., Ho, L. T. Y., Xiang, P., Chew, W. S., Lam, B. W. S., Chen, C., Ong, W., Lai, M. K. P., & Herr, D. R. (2020) · NeuroMolecular Medicine · doi:10.1007/s12017-020-08632-0 · Cited by 12 · see citing works

Druggable Sphingolipid Pathways: Experimental Models and Clinical Opportunities

Blaho, V. A. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-50621-6_6 · Cited by 12 · see citing works

Effects of fingolimod treatments on alanine transaminase and aspartate transaminase levels in patients with multiple sclerosis.

Joni, S. S., Cheshmavar, M., Shoureshi, P., Zamani, Z., Taoosi, N., Akbari, M., & Afzali, M. (2020) · PubMed Central · Cited by 10 · see citing works

Drug Repurposing for Identification of S1P1 agonists with Potential Application in Multiple Sclerosis Using in Silico Drug Design Approaches

Alizadeh, A. A., Jafari, B., & Dastmalchi, S. (2022) · Advanced Pharmaceutical Bulletin · doi:10.34172/apb.2023.012 · Cited by 9 · see citing works

SPHK1 / S1P / S1PR pathway promotes the progression of peritoneal fibrosis by mesothelial‐mesenchymal transition

Zhao, T., Ding, T., Sun, Z., Shao, X., li, S., Lu, H., Yuan, J., & Guo, Z. (2024) · The FASEB Journal · doi:10.1096/fj.202301323r · Cited by 9 · see citing works

Prognostic significance of neurofilament light in Fingolimod therapy for Multiple Sclerosis: A systemic review and meta-analysis based on randomized control trials

Ashkar, A., Baig, M. M. A., Arif, A., Ali, M. M., Yousuf, F., & Ashkar, R. (2022) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2022.104416 · Cited by 8 · see citing works

Inhibiting sphingosine 1-phosphate lyase: From efficacy to mechanism

George, N., & Xiao, J. (2024) · Neurobiology of Disease · doi:10.1016/j.nbd.2024.106585 · Cited by 8 · see citing works

Lysophosphatidic acid (LPA)-antibody (504B3) engagement detected by interferometry identifies off-target binding

Ray, M., Kihara, Y., Bornhop, D. J., & Chun, J. J. M. (2021) · Lipids in Health and Disease · doi:10.1186/s12944-021-01454-4 · Cited by 7 · see citing works

Disease-modifying therapies do not affect sleep quality or daytime sleepiness in a large Australian MS cohort

Turner, J. A., Laslett, L. L., Padgett, C. R., Lim, C. K., Taylor, B. V., van der Mei, I. A. F., & Honan, C. A. (2023) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2023.104902 · Cited by 7 · see citing works

Blocking sphingosine 1-phosphate receptor 1 with modulators reduces immune cells infiltration and alleviates endometriosis in mice

Zhang, F., Peng, M., Zheng, X., Wang, X., Liu, X., Chen, C., & Lu, Y. (2023) · Reproductive BioMedicine Online · doi:10.1016/j.rbmo.2023.103304 · Cited by 7 · see citing works

Sphingosine 1-Phosphate Lyase in the Developing and Injured Nervous System: a Dichotomy?

Xiao, J. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03524-3 · Cited by 8 · see citing works

From diagnosis to treatment: exploring the mechanisms underlying optic neuritis in multiple sclerosis

Tong, B., Zhang, X., Hu, H., Yang, H., Wang, X., Zhong, M., Yang, F., & Hua, F. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06105-1 · Cited by 7 · see citing works

GPCRs as an emerging host‐directed therapeutic target against mycobacterial infection: From notion to reality

Naz, F., & Arish, M. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15315 · Cited by 7 · see citing works

Potential therapeutic strategies in chronic inflammatory demyelinating polyradiculoneuropathy

Hu, J., Zhao, C., & Lin, J. (2022) · Autoimmunity Reviews · doi:10.1016/j.autrev.2022.103032 · Cited by 7 · see citing works

Primary central nervous system lymphoma in a patient with multiple sclerosis using fingolimod

Morillos, M. B., de Aguiar, P. H. P., Franceschini, P. R., Duarte, J. Á., Piccini, C. D., & Finkelsztejn, A. (2022) · Neurological Sciences · doi:10.1007/s10072-022-06367-3 · Cited by 7 · see citing works

Sphingosine 1-phosphate receptor modulators for the treatment of inflammatory bowel disease and other immune-mediated diseases

Xu, L., Lu, P., & Wang, Y. (2022) · Medicinal Chemistry Research · doi:10.1007/s00044-022-02961-4 · Cited by 7 · see citing works

Recent Insight into the Role of Sphingosine-1-Phosphate Lyase in Neurodegeneration

Wieczorek, I., & Strosznajder, R. P. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076180 · Cited by 7 · see citing works

Sphingosine-1-Phosphate as Lung and Cardiac Vasculature Protecting Agent in SARS-CoV-2 Infection

Karam, M., & Auclair, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713088 · Cited by 7 · see citing works

Introduction: Druggable Lipid Signaling Pathways

Kihara, Y. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-50621-6_1 · Cited by 7 · see citing works

Fingolimod Suppresses NLRP3 Inflammasome Activation and Alleviates Oxidative Stress in Traumatic Brain Injury-Induced Acute Lung Injury

Shi, Q., Hu, T., Xu, L., Fu, J., Fang, Y., Lan, Y., Fan, W., Wu, Q., Tong, X., & Yan, H. (2025) · Journal of Inflammation Research · doi:10.2147/jir.s503428 · Cited by 6 · see citing works

Introduction to the Theme “New Therapeutic Targets”

Insel, P. A., Amara, S. G., Blaschke, T. F., & Meyer, U. (2019) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-101018-112717 · Cited by 6 · see citing works

Deletion of Sphingosine 1‐Phosphate receptor 1 in cardiomyocytes during development leads to abnormal ventricular conduction and fibrosis

Jorgensen, R. M., Katta, M. H., Wolfe, J. T., Leach, D. F., Lavelle, B., Chun, J. J. M., & Wilsbacher, L. D. (2021) · Physiological Reports · doi:10.14814/phy2.15060 · Cited by 6 · see citing works

Sphingosine 1-Phosphate Receptor 5 (S1P5) Knockout Ameliorates Adenine-Induced Nephropathy

Eckes, T., Patyna, S., Koch, A. H., Oftring, A., Gauer, S., Obermüller, N., Schwalm, S. A., Schaefer, L., Chun, J. J. M., Gröne, H., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073952 · Cited by 6 · see citing works

In-silico characterization of deleterious non-synonymous SNPs in the human S1PR1 gene reveals structural instability and altered ligand affinity

Biswas, S., Sardar, D., Hossain, M. A., Hasnat, S., Ramjan, A. H., Nazifa, U. K., Zohora, F.-T., Esha, I. J., Mondal, C., Barik, A., et al. (2026) · PLoS ONE · doi:10.1371/journal.pone.0339370 · Cited by 5 · see citing works

T-cell infiltration in the central nervous system and their association with brain calcification in Slc20a2-deficient mice

Zhang, Y., Ren, Y., Zhang, Y., Li, Y., Xu, C., Peng, Z., Jia, Y., Qiao, S., Zhang, Z., & Shi, L. (2023) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2023.1073723 · Cited by 5 · see citing works

LPA2 Alleviates Septic Acute Lung Injury via Protective Endothelial Barrier Function Through Activation of PLC-PKC-FAK

Bai, R., Pei, J., Pei, S., Cong, X., Chun, J. J. M., Wang, F., & Chen, X. (2023) · Journal of Inflammation Research · doi:10.2147/jir.s419578 · Cited by 5 · see citing works

Pseudoirreversible inhibition elicits persistent efficacy of a sphingosine 1-phosphate receptor 1 antagonist

Maruyama, Y., Ohsawa, Y., Suzuki, T., Yamauchi, Y., Ohno, K., Inoue, H., Yamamoto, A., Hayashi, M., Okuhara, Y., Muramatsu, W., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-49893-8 · Cited by 4 · see citing works

S1PR3 inhibition impairs cell cycle checkpoint via the AKT/WEE1 pathway in oral squamous cell carcinoma

Xin Min, Z. H. O. U., Liu, J., Xu, C. Y., Zhou, X., Xu, B., Gan, G., & Chen, F. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06582-4 · Cited by 4 · see citing works

Generation of an Lpar1-EGFP Fusion Knock-in Transgenic Mouse Line

Rivera, R. R., Williams, N., Kennedy, G. G., Sánchez-Pavón, P., & Chun, J. J. M. (2021) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-021-01033-5 · Cited by 4 · see citing works

A Pipeline to Investigate the Structures and Signaling Pathways of Sphingosine 1-Phosphate Receptors

Cheng, L., Su, L., Tian, X., Xia, F., Zhao, C. S., Yan, W., & Shao, Z. (2022) · Journal of Visualized Experiments · doi:10.3791/64054 · Cited by 4 · see citing works

Differential diagnosis between NMOSD and MS: a retrospective study based on clinical and imaging features

Ma, Y., Wang, Q., Ma, S.-R., Yang, L., Ding, Y., & Wu, Q. (2026) · Frontiers in Neurology · doi:10.3389/fneur.2026.1718736 · Cited by 3 · see citing works

Central Versus Peripheral Drug Exposure Ratio, a Key Differentiator for Siponimod Over Fingolimod?

Bigaud, M., Ramseier, P., Tisserand, S., Lang, M., Urban, B., Beerli, C., & Karlsson, G. (2023) · Neurology and Therapy · doi:10.1007/s40120-023-00487-4 · Cited by 3 · see citing works

Cytokine Gene Expression and Treatment Impact on MRI Outcomes in Jordanian Patients with Multiple Sclerosis

Khdair, S. I., Waleed, M., Hammad, A. M., Al-Khareisha, L., Jaber, T., Ayash, M., & Hall, F. S. (2025) · Life · doi:10.3390/life15060859 · Cited by 3 · see citing works

Forest fungi: Advancement of White biotechnology via forest fungi

Raturi, S., & Kumari, S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-18870-1.00019-6 · Cited by 3 · see citing works

Lysophospholipid (S1P) receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database

Blaho, V. A., Chun, J. J. M., Jonnalagadda, D., Kihara, Y., Mizuno, H., Mpamhanga, C., Spiegel, S., & Tan, V. P. (2019) · IUPHAR/BPS Guide to Pharmacology CITE · doi:10.2218/gtopdb/f135/2019.4 · Cited by 3 · see citing works

Discovery and SAR study of highly selective and potent 1,2,4-oxadiazole-based S1PR1 agonists

Ye, T., Yu, J., Fang, Y., Xu, Z., Guo, S., Zhao, Z., Li, H., He, H., & Zhu, L. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118097 · Cited by 2 · see citing works

Effects of Sphingosine-1-Phosphate on the Facilitation of Peripheral Nerve Regeneration

Li, C., Yamamoto, T., Kanemaru, H., Kishimoto, N., & Seo, K. (2024) · Cureus · doi:10.7759/cureus.73784 · Cited by 2 · see citing works

Preparation and In vitro/In vivo Evaluation of Fingolimod hydrochloride Loaded Polymeric Mixed Nano-Micelles for Treatment of Multiple Sclerosis

Dayani, L., Haddadi, F., Aliomrani, M., & Taheri, A. (2025) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-025-10203-8 · Cited by 2 · see citing works

Oligodendrocytes interactions with glial cells and neurons in demyelinating disease

He, J., Sun, Q., Li, X., Du, R., Xue, H., Zhang, Y., & Li, X. (2025) · Acta Biochimica et Biophysica Sinica · doi:10.3724/abbs.2025105 · Cited by 1 · see citing works

Microglia-independent rAAV-induced inflammation causes persistent ocular immune dysregulation rescued by S1P receptor modulation

Langer, P. M., Clare, A. J., Peng, X., Costello, K. L., Cendanawati, S., Wilson, L. L., Ward, A., Bell, O. H., Chu, C. J., Chan, Y., et al. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.02.018 · Cited by 1 · see citing works

Function and Modulation of Sphingosine-1-Phosphate Receptors in the Central Nervous System

Gulliksen, E., Darsi, S., Haidarbaigi, L., Codispoti, L. J., Purohit, D. J., Jung, A., Chilamula, A., & Newton, J. C. (2026) · Receptors · doi:10.3390/receptors5010009 · Cited by 1 · see citing works

Lymphatic dysfunction and ZFP36 deficiency contribute to myxomatous valve degeneration in Marfan syndrome mice

Tan, C., Ren, Z., Kurup, S., Xianpeng, L., Ge, Z., Suzuki, S., Jakka, P., Tang, C., Iruela‐Arispe, M. L., & Kume, T. (2026) · Journal of Clinical Investigation · doi:10.1172/jci195507 · Cited by 1 · see citing works

Chronic disseminated histoplasmosis in a patient on fingolimod therapy: A case report and review of literature

Sanjeevi, A., Clark, B., Aguirre, A., & Verghese, B. G. (2024) · Clinical Immunology Communications · doi:10.1016/j.clicom.2024.06.002 · Cited by 1 · see citing works

Nanocarriers and Nano Drug Delivery Therapy in Neuro Diseases

Rana, P., Kaur, G., Chirayimmel, A. J., Rajput, A., Rath, S. K., & Dwibedi, V. (2024) · Smart nanomaterials technology · doi:10.1007/978-981-97-0308-1_10 · Cited by 1 · see citing works

The protective effect of Fingolimod upon visual behavior in a demyelination animal model is associated with synaptopathy prevention

de Pádua, A. C., da Cruz, S. A. A., Heringer, L. D. S., Pires, G. N., Raquita, D. A. D. S., Tavares, J. D. S., Rodrigues, P. S., Sá, A. C. D. S. G., de Barros, C. M., Seabra, S. H., et al. (2025) · NeuroToxicology · doi:10.1016/j.neuro.2025.03.004 · Cited by 1 · see citing works

FTY720 alleviates HBV-mediated inflammatory liver injury through a dual role of inhibiting lymphocyte trafficking and viral replication

Liu, J., Zhao, Y., Song, Y., Zhang, L., Han, X., Liu, L., Li, M., Wang, L., Wu, Y., & Han, Q.-Z. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114495 · Cited by 1 · see citing works

Screening of the FDA-approved drug library identifies CCL17 inhibitors that block arthritic pain

Eivazitork, M., Lupancu, T. J., Lim, K. K. T., Huang, Y., Hamilton, J. A., Lee, M.-C., & Achuthan, A. A. (2025) · Scientific Reports · doi:10.1038/s41598-025-12191-4 · Cited by 1 · see citing works

A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya).

Chun, J. J. M., & Brinkmann, V. (2011) · PubMed · Cited by 177 · see citing works

Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis

Brinkmann, V., Billich, A., Baumruker, T., Heining, P., Schmouder, R., Francis, G., Aradhye, S., & Burtin, P. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3248 · Cited by 1,273 · see citing works

Fingolimod: A Novel Oral Immunomodulatory Treatment For Multiple Sclerosis

Javed, A., & Soliven, B. C. (2011) · Future Neurology · doi:10.2217/fnl.11.15

Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis

Cohen, J. A., & Chun, J. J. M. (2011) · Annals of Neurology · doi:10.1002/ana.22426 · Cited by 394 · see citing works

Modulation of sphingosine 1-phosphate signaling in neurologic disease

Antel, J. P., & Hohlfeld, R. (2011) · Neurology · doi:10.1212/wnl.0b013e31820d5e55 · Cited by 1 · see citing works